Chung Tae-Wook, Kim Eun-Yeong, Han Chang Woo, Park So Young, Jeong Mi Suk, Yoon Dahye, Choi Hee-Jung, Jin Ling, Park Mi-Ju, Kwon Yun Ju, Lee Hanna, Kim Keuk-Jun, Park Kang Hyun, Kim Suhkmann, Jang Se Bok, Ha Ki-Tae
Department of Korean Medical Science, Healthy Aging Korean Medical Research Center, Pusan National University, Yangsan, Gyeongsangnam-do 50612, Korea.
Graduate Training Program of Korean Medicine for Healthy-aging, Pusan National University, Yangsan, Gyeongsangnam-do 50612, Korea.
Cancers (Basel). 2019 Jul 9;11(7):963. doi: 10.3390/cancers11070963.
Lactate dehydrogenase A (LDHA) is an important enzyme responsible for cancer growth and energy metabolism in various cancers via the aerobic glycolytic pathway. Here, we report that machilin A (MA), which acts as a competitive inhibitor by blocking the nicotinamide adenine dinucleotide (NAD) binding site of LDHA, suppresses growth of cancer cells and lactate production in various cancer cell types, including colon, breast, lung, and liver cancers. Furthermore, MA markedly decreased LDHA activity, lactate production, and intracellular adenosine triphosphate (ATP) levels induced by hypoxia-induced LDHA expression in cancer cells, and significantly inhibited colony formation, leading to reduced cancer cell survival. In mouse models inoculated with murine Lewis lung carcinoma, MA significantly suppressed tumor growth as observed by a reduction of tumor volume and weight; resulting from the inhibition of LDHA activity. Subsequently, the suppression of tumor-derived lactic acid in MA-treated cancer cells resulted in decrease of neovascularization through the regulation of alternatively activated macrophages (M2) polarization in macrophages. Taken together, we suggest that the reduction of lactate by MA in cancer cells directly results in a suppression of cancer cell growth. Furthermore, macrophage polarization and activation of endothelial cells for angiogenesis were indirectly regulated preventing lactate production in MA-treated cancer cells.
乳酸脱氢酶A(LDHA)是一种重要的酶,它通过有氧糖酵解途径在多种癌症中参与癌症生长和能量代谢。在此,我们报告马奇灵A(MA)通过阻断LDHA的烟酰胺腺嘌呤二核苷酸(NAD)结合位点而作为竞争性抑制剂,可抑制包括结肠癌、乳腺癌、肺癌和肝癌在内的多种癌细胞类型的生长及乳酸生成。此外,MA显著降低癌细胞中缺氧诱导的LDHA表达所诱导的LDHA活性、乳酸生成及细胞内三磷酸腺苷(ATP)水平,并显著抑制集落形成,从而降低癌细胞存活率。在接种小鼠Lewis肺癌的小鼠模型中,MA通过抑制LDHA活性,显著抑制肿瘤生长,表现为肿瘤体积和重量减小。随后,MA处理的癌细胞中肿瘤衍生乳酸的抑制导致通过调节巨噬细胞中交替活化巨噬细胞(M2)极化而减少新生血管形成。综上所述,我们认为MA降低癌细胞中的乳酸直接导致癌细胞生长受到抑制。此外,MA处理的癌细胞中乳酸生成的抑制间接调节巨噬细胞极化和内皮细胞的血管生成激活。